Influence of the in vivo half-antibody exchange on the therapeutic efficacy of an IgG4 antibody-drug conjugate
A high number of therapeutic antibodies and their derivates e.g. antibody-drug conjugates (ADC) are under preclinical or clinical evaluation for the treatment of cancer. Most of those ADCs are based on the IgG1 or IgG4 subtype, depending on whether additional effector functions are desired or not. I...
|Online Access:||PDF Full Text|
No Tags, Be the first to tag this record!